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ﬁ14th International Congress on Infectious Diseases (ICID) Abs
patients. Surveillance for H1N1 requiring documented fever
will underestimate burden of disease. Children <5 years old
in Guatemala should be prioritized for vaccination.
doi:10.1016/j.ijid.2010.02.2202
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Background: Trivalent seasonal inﬂuenza vaccine (TIV)
adjuvanted with the emulsion adjuvant MF59® (FLUAD®)
is licensed in 29 countries worldwide for adults over 65
years of age. Compared with unadjuvanted TIV, the adju-
vanted vaccine provides higher hemagglutination inhibition
(HI) antibody titers not only against vaccine strains, but also
against drift-variant strains. Usually inﬂuenza is transmitted
in a single epidemic seasonal epidemic in temperate cli-
mates, but it may appear in two epidemics during the year
or may be transmitted throughout the year, in subtropical
and tropical locations. Although persons travelling from the
Northern Hemisphere (NH) to the tropics or antipodes may
not have access to the TIV made with strains used in the
Southern Hemisphere (SH) formulation, they are neverthe-
less recommended to receive available NH formulation-TIV
because one or more of the strains may overlap and because
some degree of protection may be elicited, even by an
imperfectly matched vaccine.
Methods: The following data from recent clinical
trials highlight the cross-protection elicited by the MF59-
adjuvanted vaccine. Sera from 222 children, 6-36 months of
age, vaccinated with the 2006/07 formulations of FLUAD or
unadjuvanted TIV were tested against the H1N1 strain in the
2007/08 formulation (A/Solomon Islands/3/2006 (H1N1)-
like). Sera from adults with chronic illnesses and elderly
adults (> 65 years) were similarly tested.
Results: In the children geometric mean titer (GMT) HI
responses, geometric mean ratios (GMR), and seroprotec-
tion (SP) rates were signiﬁcantly higher in FLUAD recipients.
Similar signiﬁcant differences were seen among 349 adults
with chronic illnesses with increased risk for inﬂuenza mor-
bidity who were vaccinated with either FLUAD or with an
undajuvanted subunit vaccine. Finally, 56 elderly adults who
received the 2007/08 FLUAD formulation displayed postvac-
cination responses against strains in the 2008/09 formulation
which met the European Committee for Human Medicinal
Products criteria for GMR, SP and SC for the mismatched
H1N1 and H3N2 strains.
Conclusion: Altogether these results suggest that the
greater degree of cross-variant immunity elicited by MF59-
adjuvanted inﬂuenza vaccine may offer an advantage in
circumstances where travelers may be exposed to antigeni-
cally mismatched viruses.
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easonal inﬂuenza vaccine may be associated with
ncreased risk of illness due to the 2009 pandemic A/H1N1
irus
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Background: In late spring 2009, concern was raised in
anada that prior receipt of the 2008-09 trivalent inacti-
ated inﬂuenza vaccine (TIV) was associated with increased
isk of pandemic H1N1 (pH1N1) illness. Several epidemio-
ogic investigations were urgently conducted through the
ummer to assess this putative association.
Methods: Studies included: (1) test-negative case-control
esign based on Canada’s ongoing sentinel vaccine effective-
ess monitoring system in British Columbia, Alberta, Ontario
nd Quebec; (2) conventional case-control design using pop-
lation controls in Quebec; (3) testnegative case-control
esign in Ontario and (4) prospective household transmis-
ion (cohort) study in Quebec. Logistic regression estimated
dds ratios for TIV effect on community- or hospital-based
aboratory-conﬁrmed seasonal or pH1N1 inﬂuenza cases
ompared to controls with restriction, stratiﬁcation and
djustment for covariates including combinations of age,
ex, comorbidity, timeliness of medical visit, prior physician
isits, and/or health care worker status. For the prospective
tudy relative risks were computed.
Results: Based on the sentinel study of ∼700 cases and
00 controls, 2008-09 TIV provided statistically signiﬁcant
rotection against seasonal inﬂuenza (OR 0.44;95% CI 0.33-
.59). Conversely, estimates from the sentinel and several
ther study designs involving ∼1200 laboratory-conﬁrmed
H1N1 cases and 1500 controls consistently showed that
rior recipients of 2008-09 TIV were at statistically sig-
iﬁcant 1.5-2.5-fold increased risk of medically-attended
H1N1 illness during the spring/summer 2009 with upper
imit of the 95% conﬁdence interval spanning 3-4-fold
ncrease. There was non-signiﬁcant increase in the strength
f the association with more TIV doses received in the prior
ve years. Risk of pH1N1 hospitalization was not further
ncreased among vaccinated people when comparing hos-
italized to community cases.
Conclusion: Prior receipt of 2008-09 TIV was associ-
ted with increased risk of medicallyattended pH1N1 illness
uring the spring/summer 2009 in Canada. Possible biologi-
